This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford. His research focuses on the development of bigdata machine learning for tracking the health of complex systems. Mark holds a PhD in biomedicine, and an MSc in biostatistics.
In 2021, Komodo acquired two companies: Mavens, a developer of cloud-based software used for speciality biotech and pharma companies, and Breakaway Partners, a market access software company targeting the lifesciences industry. He oversees operations, including businessdevelopment, sales and marketing, and people.
He oversees operations, including businessdevelopment, sales and marketing, and people. He also serves as an executive advisor to Reify Health, Heads Up Health , and other healthcare/healthtech start-ups focused on bigdata, SaaS, healthcare IT (HIT), and predictive analytics to improve patient outcomes.
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through businessdevelopment activities. 2022 Revenue: In 2022, Merck KGaA (LifeScience and Healthcare divisions only) had an annual revenue of €18.22
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content